CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy

<div><b>Recurrence-free survival</b>. Figure <a href="../fig4/">4</a> shows curves comparing recurrence-free survival in patients with CDK9 positive versus CDK9 negative tumors. There is no statistically significant or observable difference in the two survival curves.</div>

International Journal of Breast Cancer

fig4

Figure 4

Figure 4: CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy 

Figure 4 | CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy 